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Summary 
Dynorphin and an opiate-inactive fragment 
des-Tyr-dynorphin produced similar effects on 
EEG, motor function and hippocampal unit firing. 
Naloxone had no effect on the actions of 
dynorphin in these systems and dynorphin failed 
to produce analgesia upon central administra- 
tion. These results suggest that dynorphin has 
a pharmacological character that differs sign- 
ificantly from the classic narcotics. 
Dynorphin is detected in substantial quantity both in the 
brain and in the pituitary (1,2). Early work indicated that the 
in vivo pharmacology of dynorphin [1-13] differs significantly 
from other enkephalin-containing peptides in that it is a poor 
analgesic, and produces unusual motoric and behavioral effects 
(3-6). Moreover, a number of its effects were unaffected by 
naloxone. Upon the final sequencing of the last four 
amino-acids (5) it was of interest to determine whether or not 
these unique effects of dynorphin would occur with the full 
molecule. We find that a fragment of dynorphin, des-Tyr- 
dynorphin, fails to bind to opiate receptors in vitro, but 
produces pharmacological effects similar to those of the parent 
compound. Consistent with this finding we demonstrate that 
naloxone fails to influence the effects of dynorphin on EEG, 
motor-function, and hippocampal unit discharge rate. It seems 
likely from these results that dynorphin produces some effects 
through a non-opiate but highly sensitive mechanism. 
MATERIALS AND METHODS 
Surgery: Surgery was carried out on male Sprague-Dawiey 
rats for permanent placement of bipolar cortical (area 6) and 
dorsal hippocampal EEG electrodes using the methods described by 
Robinson (7). A 24 ga stainless steel cannula was implanted in 
the lateral ventricle using methods we have already described 
(8). All injections were made using a microsyringe with a 31 ga 
needle and in a volume of 5 ul. The correct placement of 
cannulas was verified histologically in all animals. 
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PhYsioiogica! Recordin@: The EEG was recorded differen- 
tially on a Grass Model 7B polygraph (i Hz and 75 Hz cutoff 
filters). Eight animals underwent treatment with 5, i0, 20 ug 
of dynorphin and an artificial CSF control. Six animals were 
tested with dynorphin ten minutes after intraperitoneal 
administration of either 20 mg/kg naloxone HCI or saline. A 
final group of 6 rats was treated with 20 ug dynorphin and with 
20 ug des-Tyr-dynorphin. After these experiments some animals 
were also tested with B-endorphin (i0 ug) or ethylketocyclazo- 
cine (25 ug) ICV. 
Binding.Assays: The ability of dynor~hin and des-Tyr- 
~ynorphi 9 to , displace H-morphine, -H-UMI071, and 
-H-D-Ala~-D-Leu~-enkephalin (DADLE) from rat brain homogenate 
was carried out using procedures similar to those described by 
Akil et al. (9). 
Unit Recording, Iontophq[esist Pressure Micro-ejection: 
Single cell recording and iontophoresis were carried out with 
five barreled glass micro-electrodes (i0). The recording barrel 
was filled with 4 M NaCi saturated with fast green dye. A side 
barrel filled with 4 M NaCI was used for current balancing and 
to test for current artifacts. 
Dynorphin and des-Tyr-dynorphin were ejected either by 
electro-osmosis (4 mM in .9% NaCl) or by air pressure (.5-30 
psi). In some cases the remaining barrel was filled with 
naloxone (50 mM pHS.5); in other experiments it was filled with 
L-glutamate (250 mM, pH 8.0) which was used in a few cases to 
increase the activity of slowly firing cells. Animals were 
anesthetized with chloral hydrate and maintained in deep 
anesthesia with supplemental injections. Hippocampal pyramidal 
cells (CA1 and CA3) were identified by their depth and typical 
bursting pattern of firing. These cells were of particular 
interest because they appear to receive substantial input from 
dynorphin containing fibers (13). 
Anal esia Testin - The ffect o on n .@ ..... q. e f dynorphin pai 
sensitivlty was assessed using the tail flick test (n=8). A 
cannula aimed for the lateral ventricle was stereotaxically 
placed as described above. Methods used for the tail flick test 
have been described elsewhere (8). Tail-flick latencies were 
recorded at 3 minute intervals before and after administration 
of dynorphin (20 ug, ICY) or artificial CSF. The order of the 
administration of the drug and control solution was 
counterbalanced and 48 hours intervened between tests. For each 
animal an estimate of the degree of analgesia was computed by a 
mathematical (Simpsons) approximation of the integral of the 
change from the mean baseline. These scores were subjected to 
repeated measures analysis of variance. 
RESULTS 
Dyn~rphin had an ICoN of 12 nM~against 3H-morphine, 40 nM 
against H-DADLE, and tO0 nM for -H-UMI071. Des-Tyr-dynorphin 
failed to show displacement 3 of any rad~o-ligand at 
concentrations up to 125 nM for H-morphine and H-DADLE and up 
to i uM for ~H-UMI071. It thus appeared that this fragment 
would be a useful probe for non-opiate actions of dynorphin. 
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The pattern of the results of the physiological experiments 
with dynorphin differs significantly from those of classical 
narcotics. Dynorphin failed to produce any statistically 
significant analgesia in the tail flick test. Thus although 2 
of 8 animals showed elevations in tail flick latency, the 
overall effect of dynorphin was far from statistically 
significant (F 1,6 = 1.09, N.S.) . In fact, the dynorphin 
treatment accounted for less than 1% of the total variance in 
the experiment (w = .008). 
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Dynorphin produced seizures in some animals at all doses 
tested (5, i0, 20 ug) while seizures never occurred with the 
artificial CSF vehicle. The probability of a seizure and its 
duration were dose-related. The length of the seizure thus 
showed a strong correlation to dose (r=.79, p<.001). Seizures 
induced by dynorphin and des-Tyr-dynorphin differ in their 
characteristic appearance from those induced by D-AIa -- 
enkephalin, B-endorphin, or ethylketocyclazocine. Dynorphin 
typically produced much slower spikes in the cortex and 
depression of the hippocampal EEG, while standard narcotics 
typically produce more rapid spiking followed by a post-ictal 
depression. 
In contrast to classic narcotics (13,14), all 6 rats who 
were pro-treated with naloxone HCi (20 mg/kg ip) still showed 
seizures after micro-injection of 20 ug dynorphin icy. 
Similarly, 5 of 6 rats who showed seizt~res with dynorphin also 
showed seizures with the same dose of the opiate inactive 
fragment, des-Tyr-dynorphin. 
As shown, both dynorphin and des-Tyr-dynorphin produced 
inhibition of hippocampal pyramidal cells. Thus, 18 of 24 CA1 
cells and 18 of 24 CA3 cells were inhibited by dynorphin 
iontophoresis or pressure ejection. In marked contrast to the 
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effects of enkephalin (14), only 2 of 45 units sampled showed 
signs of excitation. Iontopho resis of naloxone failed to 
reverse or inhibit the effects of dynorphin (8 of 8 cells). 
Similarly, des-Tyr-dynorph in also inhibited hippocampal 
pyramidal cells (9 of 12 cells). 
DISCUSSION 
These results document the unique pharmacological profile 
of dynorphin in a variety of in vivo systems. Dynorphin differs 
significantly from the known narcotics both in the nature of its 
action and in its pharmacological susceptibilities. Unlike a 
wide variety of opiates, dynorphin fails to promote analgesia. 
Many narcotics induce EEG seizures as does dynorphin, but the 
seizures induced by dynorphin are not prevented by naloxone and 
appear to be equally well produced by the opiate inactive 
fragment, des-Tyr-dynorphin. 
While enkephalin and other opiates excite hippocampal 
pyramidal cells, both dynorphin and des-Tyr-dynorphin inhibit 
these cells. These effects are consistent with a number of 
reports in the literature on dynorphin [1-13], which is also 
quite potent, but not sensitive to naloxone in many cases (3-6). 
It thus appears that a second site, which is not opiate in 
nature, may exist within the dynorphin sequence. The 
physiological significance of such a proposed site and its 
precise location within the dynorphin molecule are at this point 
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